“O.itemList.length” “- this.config.text.ariaShown
“This.config.text.ariaFermé”
German biotechnology company BioNTEch (BNTX) and US pharmaceutical giant Pfizer (PFE) announced Monday (July 27) that they had submitted human trials that have been defeated this week on a possible messenger RNA vaccine (MRNA) opposed to coronavirus.
The corporations reported that up to another 30,000 people between the ages of 18 and 85 would participate in the global test at 120 sites, adding 39 U.S. states.
BioNTech CEO Ugur Sahin said in a statement that the resolution to launch the giant trial reflects “our number one purpose of bringing a well-tolerated and highly effective vaccine to market as temporarily as possible, while we will continue to compare our other candidate vaccines. component of a portfolio of differentiated COVID-19 vaccines. »
READ ALSO: COVID-19 Vaccine: GlaxoSmithKline invests millions of pounds in CureVac in Germany
Partners said that if the trials are successful, they will be on track to request a regulatory review starting in October this year. They added that if regulatory approval or approval is obtained, they “plan to supply up to one hundred million doses by the end of 2020 and around 1.3 billion doses by the end of 2021.”
Mainz-based BioNTech and Pfizer obtained approval from the German regulator to begin their first human clinical trial circular in April.
If the progression vaccine is successful, Pfizer and BioNTech will get $1.95 billion from the U.S. government. For an initial order of one hundred million doses, as a component of the government’s Operation Warp Speed program to drive the progression of coronavirus treatments.
There are around 150 vaccines in progression worldwide, according to WHO. BioNtech is one of the two leading German corporations in the world race, being CureVac. Both the German government and the pharmaceutical company GlaxoSmithKline have invested in CureVac.
Earlier this month, Oxford University researchers announced that the vaccine they were preparing was promising: it looked and triggered an immune reaction in trials involving more than 1,000 people.
Listen to the Yahoo Finance UK podcast